Argenx ARGX-113-2004
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and theSafety of Efgartigimod (ARGX-113) PH20 Subcutaneous in
Adult Patients With Primary Immune Thrombocytopenia
Argenx ARGX-113-2004
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and theSafety of Efgartigimod (ARGX-113) PH20 Subcutaneous in
Adult Patients With Primary Immune Thrombocytopenia